Gilead Fights $50M Bonus Demand After EU Cancer Drug OK
With $50 million on the line, an attorney for California-based biopharmaceutical company Gilead Sciences Inc. argued in Delaware's Chancery Court Tuesday for a science- rather than lawyer-focused interpretation of merger contract...To view the full article, register now.
Already a subscriber? Click here to view full article